Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134491 | 0.78 | MPO (0.31) | MPO | |
| SCHEMBL545834 | 0.75 | MPO (0.33) | MPO | |
| SCHEMBL183647 | 0.71 | MPO (0.36) | MPO | |
| SCHEMBL11805243 | 0.66 | MPO (0.33) | MPO | |
| SCHEMBL3801963 | 0.62 | MPO (0.36) | MPO | |
| SCHEMBL7452613 | 0.62 | — | — | |
| SCHEMBL7456782 | 0.62 | — | — | |
| SCHEMBL4146881 | 0.61 | — | — | |
| SCHEMBL157261 | 0.61 | MPO (0.33) | MPO | |
| SCHEMBL7617970 | 0.60 | MPO (0.41) | MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002509155-A | — | — | 2002-03-26 | — | — | JP | claimed |
| EP-1047705-A2 | NUCLEOBASE OLIGOMERS | THE PERKIN-ELMER CORPORATION (US) | 2000-11-02 | — | — | EP | claimed |
| US-6054568-A | Nucleobase oligomers | THE PERKIN-ELMER CORPORATION (US) | 2000-04-25 | — | — | US | claimed |
| WO-1999036429-A2 | NUCLEOBASE OLIGOMERS | THE PERKIN-ELMER CORPORATION (US) | 1999-07-22 | — | — | WO | claimed |
| US-20250313838-A1 | NUCLEIC ACID FOR TRANSFECTION | AGC Inc. (JP) | 2025-10-09 | — | — | US | disclosed |
| EP-4585684-A1 | NUCLEIC ACID FOR TRANSFECTION | AGC INC. (JP) | 2025-07-16 | — | — | EP | disclosed |
| CN-119731318-A | Nucleic acid for transfection | ＡＧＣ株式会社 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024141901-A1 | HEAT-BASED TRANSFER OF REACTION PRODUCTS MADE IN SITU TO A PLANAR SUPPORT | MOLECULENT AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| EP-4320263-B1 | DETECTION OF PROXIMITY ASSAY PRODUCTS IN SITU | MOLECULENT AB (SE) | 2024-06-19 | — | — | EP | disclosed |
| US-20240190957-A1 | HIGH-THROUGHPUT METHODS FOR ANALYZING AND AFFINITY-MATURING AN ANTIGEN-BINDING MOLECULE | 10X GENOMICS, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240192225-A1 | METHOD FOR EPITOPE BINNING OF NOVEL MONOCLONAL ANTIBODIES | 10X GENOMICS, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240140977-A1 | REVERSIBLE TERMINATORS | ANSA BIOTECHNOLOGIES, INC. | 2024-05-02 | — | — | US | disclosed |
| WO-1997001646-A2 | ELECTROCHEMICAL DETECTION OF NUCLEIC ACID HYBRIDIZATION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0411158-B1 | Process for producing nucleosides by using phosphorylases obtainable from Bacillus stearothermophilus | YAMASA SHOYU KK (JP) | 1996-05-29 | — | — | EP | disclosed |
| US-5506122-A | EXTRACTING PURINE OR PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE FROM CULTURE OF BACILLUS STEAROTHERMOPHILUS AND USED FOR FORMING NUCLEOSIDES BY REACTING PURINE OR PYRIMIDINE BASE, AS SACCHARIDE RESIDUE AND PHOPHORIC ACID | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1996-04-09 | — | — | US | disclosed |
| US-5384251-A | Culture of Bacillus to produce nucleoside phosphorylase | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1995-01-24 | — | — | US | disclosed |
| US-5258301-A | Nucleoside phosphorylase from Bacillus | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1993-11-02 | — | — | US | disclosed |
| EP-0411158-A1 | Process for producing nucleosides by using phosphorylases obtainable from Bacillus stearothermophilus | Yamasa Shoyu Kabushiki Kaisha (Yamasa Corporation) (JP) | 1991-02-06 | — | — | EP | disclosed |
| EP-0233493-A2 | Process for producing ribonucleosides | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-08-26 | — | — | EP | disclosed |
| US-4269839-A | MUSCLE RELAXANTS AND ANTISPASMODIC AGENTS; RESPIRATORY SYSTEM DISORDERS | BRISTOL-MYERS COMPANY (US) | 1981-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140977-A1 | REVERSIBLE TERMINATORS | RNGTT, TYMP, TYMS | MPO 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.